Retension Pharmaceuticals, Inc. has released its Q3 2026 financial results, highlighting its strategic positioning in the pharmaceutical preparations market.
| Name | Retension Pharmaceuticals, Inc. |
|---|---|
| CIK | 0002002988 |
| Tickers | RTSN |
| Exchanges | Nasdaq |
| Entity type | operating |
| Category | Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company |
| SIC | 2834 Pharmaceutical Preparations |
| EIN | 932592788 |
| LEI | — |
| Fiscal year end | 1231 |
| State of incorporation | DE DE |
| Phone | (703) 624-2024 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 0 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
Retension Pharmaceuticals, Inc. has released its Q3 2026 financial results, highlighting its strategic positioning in the pharmaceutical preparations market.
Retension Pharmaceuticals, Inc. announces its financial results for Q3 2026, highlighting its ongoing growth in the pharmaceutical preparations sector.
Retension Pharmaceuticals' Robert Wong files Form 3, indicating recent stock acquisition, reflecting confidence in the company's future.
Retension Pharmaceuticals' director Franklin M. Berger reports key stock transactions, reflecting ongoing activity in the pharmaceutical preparations sector.
Retension Pharmaceuticals, Inc. director Michael J. Berendt disclosed stock transactions in a recent SEC filing, indicating ongoing developments in the company.
Retension Pharmaceuticals has granted stock options to director Cheruvu Pavan, reflecting a strategic move to align executive interests with shareholders.
Retension Pharmaceuticals' director, Donald Olds, acquires 5,637 shares of common stock, reflecting ongoing engagement in the pharmaceutical sector.
Retension Pharmaceuticals grants stock options to director Donald Olds, reflecting its commitment to leadership incentives in the pharmaceutical preparations industry.
Retension Pharmaceuticals, Inc. discloses changes in beneficial ownership in recent SEC filing, impacting stakeholders in the pharmaceutical preparations industry.
Retension Pharmaceuticals, Inc. grants stock options to director Franklin M. Berger, reflecting its commitment to leadership and talent retention.
Retension Pharmaceuticals, Inc. has filed an amended registration statement to raise funds through a public offering, reflecting its commitment to growth.
47 filing rows loaded from submissions recent.
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-18 | 10-Q | 10-Q | 0001104659-26-129357 | 001-43503 | 261568092 | 34 | 5725811 | 1 | 1 | |
| 2026-11-18 | 8-K | 8-K | 2.02,9.01 | 0001104659-26-129354 | 001-43503 | 261568084 | 34 | 305251 | 1 | 1 |
| 2026-11-04 | 4 | xslF345X06/ownership.xml | 0001213900-26-115968 | 5796 | ||||||
| 2026-11-04 | 3 | xslF345X06/ownership.xml | 0001213900-26-115961 | 8225 | ||||||
| 2026-10-23 | 8-K | CURRENT REPORT | 5.02,9.01 | 0001213900-26-111794 | 001-43503 | 261479689 | 34 | 254075 | 1 | 1 |
| 2026-10-22 | 4 | xslF345X06/ownership.xml | 0001213900-26-111795 | 6107 | ||||||
| 2026-10-16 | 3 | xslF345X06/ownership.xml | 0001213900-26-110379 | 5159 | ||||||
| 2026-10-16 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0001213900-26-110378 | 005-95962 | 261467129 | 34 | 16105 | |||
| 2026-10-16 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0000820434-26-000008 | 005-95962 | 261465417 | 34 | 6999 | |||
| 2026-10-15 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0000935836-26-000533 | 005-95962 | 261462873 | 34 | 6886 | |||
| 2026-10-14 | SCHEDULE 13D | xslSCHEDULE_13D_X02/primary_doc.xml | 0001213900-26-109425 | 005-95962 | 261460030 | 34 | 19177 | |||
| 2026-10-13 | S-8 | REGISTRATION STATEMENT | 0001213900-26-109109 | 333-299450 | 261459540 | 33 | 340360 | 1 | 1 | |
| 2026-10-13 | 4 | OWNERSHIP DOCUMENT | 0001213900-26-109160 | 15298 | ||||||
| 2026-10-13 | 4 | xslF345X06/ownership.xml | 0001213900-26-109159 | 11506 | ||||||
| 2026-10-13 | 4 | xslF345X06/ownership.xml | 0001213900-26-109158 | 7343 | ||||||
| 2026-10-13 | 4 | xslF345X06/ownership.xml | 0001213900-26-109157 | 5753 | ||||||
| 2026-10-13 | 4 | xslF345X06/ownership.xml | 0001213900-26-109156 | 11267 | ||||||
| 2026-10-13 | 4 | xslF345X06/ownership.xml | 0001213900-26-109155 | 8881 | ||||||
| 2026-10-13 | 4 | xslF345X06/ownership.xml | 0001213900-26-109154 | 11092 | ||||||
| 2026-10-13 | 3 | xslF345X06/ownership.xml | 0001213900-26-109153 | 8681 | ||||||
| 2026-10-13 | 8-K | CURRENT REPORT | 5.03,9.01 | 0001213900-26-109024 | 001-43503 | 261456928 | 34 | 441197 | 1 | 1 |
| 2026-10-09 | 424B4 | PROSPECTUS | 0001213900-26-108587 | 333-299024 | 261453816 | 33 | 24600305 | |||
| 2026-10-08 | EFFECT | xslEFFECTX01/primary_doc.xml | ,, | 9999999995-26-003189 | 333-299024 | 261451066 | 33 | 1804 | ||
| 2026-10-08 | 4 | xslF345X06/ownership.xml | 0001213900-26-108190 | 5662 | ||||||
| 2026-10-08 | 4 | xslF345X06/ownership.xml | 0001213900-26-108189 | 5779 | ||||||
| 2026-10-08 | 4 | xslF345X06/ownership.xml | 0001213900-26-108188 | 5798 | ||||||
| 2026-10-08 | S-1MEF | REGISTRATION STATEMENT | 0001213900-26-108143 | 333-299378 | 261450828 | 33 | 207324 | 1 | 1 | |
| 2026-10-08 | 3 | xslF345X06/ownership.xml | 0001213900-26-108141 | 4623 | ||||||
| 2026-10-08 | 3 | xslF345X06/ownership.xml | 0001213900-26-108140 | 14889 | ||||||
| 2026-10-08 | 3 | xslF345X06/ownership.xml | 0001213900-26-108139 | 9946 | ||||||
| 2026-10-08 | 3 | xslF345X06/ownership.xml | 0001213900-26-108136 | 12842 | ||||||
| 2026-10-08 | 3 | xslF345X06/ownership.xml | 0001213900-26-108135 | 16195 | ||||||
| 2026-10-08 | 3 | xslF345X06/ownership.xml | 0001213900-26-108134 | 14207 | ||||||
| 2026-10-08 | 3 | xslF345X06/ownership.xml | 0001213900-26-108133 | 11511 | ||||||
| 2026-10-08 | 3 | xslF345X06/ownership.xml | 0001213900-26-108132 | 13959 | ||||||
| 2026-10-08 | CERT | RTSN_8A_Cert_0002002988.pdf | 0001354457-26-000966 | 001-43503 | 261450112 | 34 | 180717 | |||
| 2026-10-08 | 8-A12B | FOR REGISTRATION OF CERTAIN CLASSES | 0001213900-26-107730 | 001-43503 | 261448337 | 34 | 17917 | |||
| 2026-10-07 | S-1/A | REGISTRATION STATEMENT | 0001213900-26-107572 | 333-299024 | 261447087 | 33 | 379475 | 1 | 1 | |
| 2026-10-05 | S-1/A | AMENDMENT NO. 1 TO FORM S-1 | 0001213900-26-106636 | 333-299024 | 261438778 | 33 | 25986233 | 1 | 1 | |
| 2026-09-18 | S-1 | REGISTRATION STATEMENT | 0001213900-26-101499 | 333-299024 | 261391751 | 33 | 31559589 | 1 | 1 | |
| 2026-08-14 | DRS/A | filename1.htm | 0001213900-26-090287 | 377-09081 | 261283719 | 33 | 28960941 | |||
| 2026-06-16 | DRS/A | filename1.htm | 0001213900-26-069228 | 377-09081 | 261094471 | 33 | 17354450 | |||
| 2026-05-01 | DRS/A | filename1.htm | 0001213900-26-050520 | 377-09081 | 26928163 | 33 | 17738131 | |||
| 2026-02-17 | DRS | filename1.htm | 0001213900-26-017320 | 377-09081 | 26641910 | 33 | 15833720 | |||
| 2025-05-06 | D | xslFormDX01/primary_doc.xml | 06b | 0002002988-25-000002 | 021-545343 | 25916627 | 33 | 9626 | ||
| 2024-05-15 | D/A | xslFormDX01/primary_doc.xml | 06b | 0002002988-24-000001 | 021-498860 | 24951833 | 33 | 12275 | ||
| 2023-12-05 | D | xslFormDX01/primary_doc.xml | 06b | 0002002988-23-000002 | 021-498860 | 231467285 | 33 | 12146 |
One latest value per concept from companyfacts (77 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| dei | EntityCommonStockSharesOutstanding | Entity Common Stock, Shares Outstanding | shares | 8.89M | 2026-11-16 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 | |
| ffd | NetFeeAmt | NetFeeAmt | USD | 1,226.43 | 2026-10-13 | S-8 | 2026-10-13 | 0001213900-26-109109 | |||
| ffd | TtlFeeAmt | TtlFeeAmt | USD | 1,226.43 | 2026-10-13 | S-8 | 2026-10-13 | 0001213900-26-109109 | |||
| ffd | TtlOfferingAmt | TtlOfferingAmt | USD | 14.10M | 2026-10-13 | S-8 | 2026-10-13 | 0001213900-26-109109 | |||
| ffd | TtlOffsetAmt | TtlOffsetAmt | USD | 0 | 2026-10-13 | S-8 | 2026-10-13 | 0001213900-26-109109 | |||
| ffd | TtlPrevslyPdAmt | TtlPrevslyPdAmt | USD | 0 | 2026-10-08 | S-1MEF | 2026-10-08 | 0001213900-26-108143 | |||
| us-gaap | AccountsPayableCurrent | Accounts Payable, Current | USD | 3.89M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 | |
| us-gaap | AccruedLiabilitiesCurrent | Accrued Liabilities, Current | USD | 2.77M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 | |
| us-gaap | AdditionalPaidInCapital | Additional Paid in Capital | USD | 1.09M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 | |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue | APIC, Share-based Payment Arrangement, Increase for Cost Recognition | USD | 175,391 | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares | 5.16M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | Assets | Assets | USD | 14.15M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 | |
| us-gaap | AssetsCurrent | Assets, Current | USD | 14.15M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 | |
| us-gaap | CashAndCashEquivalentsAtCarryingValue | Cash and Cash Equivalents, at Carrying Value | USD | 9.19M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | USD | 9.19M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | USD | -9.71M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 | Class of Warrant or Right, Exercise Price of Warrants or Rights | USD/shares | 7.21 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 | |
| us-gaap | ClassOfWarrantOrRightOutstanding | Class of Warrant or Right, Outstanding | shares | 349,930 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 | |
| us-gaap | CommonStockParOrStatedValuePerShare | Common Stock, Par or Stated Value Per Share | USD/shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 | |
| us-gaap | CommonStockSharesAuthorized | Common Stock, Shares Authorized | shares | 36.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 | |
| us-gaap | CommonStockSharesIssued | Common Stock, Shares, Issued | shares | 807,928 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 | |
| us-gaap | CommonStockSharesOutstanding | Common Stock, Shares, Outstanding | shares | 807,928 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 | |
| us-gaap | CommonStockValue | Common Stock, Value, Issued | USD | 81 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 | |
| us-gaap | DeferredOfferingCosts | Deferred Offering Costs | USD | 2.49M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 | |
| us-gaap | EarningsPerShareBasic | Earnings Per Share, Basic | USD/shares | -16.65 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | EarningsPerShareDiluted | Earnings Per Share, Diluted | USD/shares | -16.65 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | ForeignCurrencyTransactionGainLossBeforeTax | Foreign Currency Transaction Gain (Loss), before Tax | USD | -856 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | GeneralAndAdministrativeExpense | General and Administrative Expense | USD | 2.57M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | IncreaseDecreaseInAccountsPayableTrade | Increase (Decrease) in Accounts Payable, Trade | USD | 3.07M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | IncreaseDecreaseInAccruedLiabilities | Increase (Decrease) in Accrued Liabilities | USD | 672,045 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | IncreaseDecreaseInDueToRelatedPartiesCurrent | Increase (Decrease) in Due to Related Parties, Current | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets | Increase (Decrease) in Prepaid Expense and Other Assets | USD | 134,444 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | InvestmentIncomeInterest | Investment Income, Interest | USD | 351,457 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | Liabilities | Liabilities | USD | 6.66M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 | |
| us-gaap | LiabilitiesAndStockholdersEquity | Liabilities and Equity | USD | 14.15M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 | |
| us-gaap | LiabilitiesCurrent | Liabilities, Current | USD | 6.66M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 | |
| us-gaap | NetCashProvidedByUsedInFinancingActivities | Net Cash Provided by (Used in) Financing Activities | USD | -294,607 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | NetCashProvidedByUsedInOperatingActivities | Net Cash Provided by (Used in) Operating Activities | USD | -9.42M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | NetIncomeLoss | Net Income (Loss) Attributable to Parent | USD | -13.44M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | NonoperatingIncomeExpense | Nonoperating Income (Expense) | USD | 350,601 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | NumberOfOperatingSegments | Number of Operating Segments | segment | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | NumberOfReportableSegments | Number of Reportable Segments | segment | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | OperatingExpenses | Operating Expenses | USD | 13.79M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | OperatingIncomeLoss | Operating Income (Loss) | USD | -13.79M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | PaymentsForRoyalties | Payments for Royalties | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | PaymentsOfStockIssuanceCosts | Payments of Stock Issuance Costs | USD | 297,543 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | PrepaidExpenseAndOtherAssetsCurrent | Prepaid Expense and Other Assets, Current | USD | 2.47M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 | |
| us-gaap | ProceedsFromStockOptionsExercised | Proceeds from Stock Options Exercised | USD | 3,961 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | ProfitLoss | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | USD | -13.44M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | ResearchAndDevelopmentExpense | Research and Development Expense | USD | 11.22M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | RetainedEarningsAccumulatedDeficit | Retained Earnings (Accumulated Deficit) | USD | -21.76M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 | |
| us-gaap | ShareBasedCompensation | Share-based Payment Arrangement, Noncash Expense | USD | 417,047 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | pure | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | pure | 0 | 2025-01-01 | 2025-12-31 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum | pure | 0.603 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum | pure | 0.575 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | pure | 0 | 2025-01-01 | 2025-12-31 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum | pure | 0.044 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum | pure | 0.042 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | shares | 542,456 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | USD/shares | 1.72 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period | shares | 15,656 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price | USD/shares | 2.43 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares | 402,583 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | shares | 1.23M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | USD/shares | 2.1 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 | |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | USD/shares | 1.43 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | USD/shares | 2.43 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | StockholdersEquity | Stockholders' Equity Attributable to Parent | USD | -20.66M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 | |
| us-gaap | StockIssuedDuringPeriodSharesStockOptionsExercised | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares | 2,774 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | StockIssuedDuringPeriodValueStockOptionsExercised | Stock Issued During Period, Value, Stock Options Exercised | USD | 639 | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | TemporaryEquityCarryingAmountAttributableToParent | Temporary Equity, Carrying Amount, Attributable to Parent | USD | 28.15M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 | |
| us-gaap | TemporaryEquitySharesAuthorized | Temporary Equity, Shares Authorized | shares | 23.44M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 | |
| us-gaap | TemporaryEquityStockIssuedDuringPeriodValueNewIssues | Temporary Equity, Stock Issued During Period, Value, New Issues | USD | 2.40M | 2025-07-01 | 2025-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic | Undistributed Earnings (Loss) Allocated to Participating Securities, Basic | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | WeightedAverageNumberOfDilutedSharesOutstanding | Weighted Average Number of Shares Outstanding, Diluted | shares | 807,287 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |
| us-gaap | WeightedAverageNumberOfSharesOutstandingBasic | Weighted Average Number of Shares Outstanding, Basic | shares | 807,287 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-18 | 0001104659-26-129357 |